Source: Medicines Authority (MT) Revision Year: 2020 Publisher: Ferrer Internacional, S.A., Gran Via Carlos III, 94, 08028 Barcelona, Spain
ATC Code: R02AA
Products for the throat. Topical Antiseptics.
The efficacy of Anginovag have been evaluated “in vivo” and “in vitro” tests. Anginovag inhibits the growth of pathogen germs in both kinds of test. Besides eliminate the pain immediately after the application and reduce the inflammation in a short time.
It have been not possible to make a classic pharmacokinetic study with Anginovag because the product does not produce suffice systemic levels of active ingredients to evaluate them.
Anginovag has a very low toxicity rate which confers it a broad safety margin. The long-term administration does not show toxic effects, due to the exclusive topical action.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
